JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
MPT
Medical Properties Trust, Inc.
There isn't enough reported data to score MPT yet.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
MPT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
MPT's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like MPT.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
MPT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.2x | $1.71 | — |
| Cheap | 7.1x | $2.90 | +70% |
| Fair | 22x | $8.96 | +424% |
| Expensive | 26x | $10.48 | +513% |
Historical ranges are pointers, not guarantees.
MPT has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
JPM has the edge over MPT on the outlook, with more favorable earnings and revenue expectations.
MPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Stable | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect MPT's earnings and profitability to decline, with its revenue holding steady.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over MPT on earnings, with more consistent year-over-year improvement.
MPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.41 | +$1.58 |
| Q2 2026 | -$0.06 | +$2.32 |
| Q1 2026 | -$0.21 | +$2.55 |
| Q4 2025 | -$0.46 | +$3.56 |
| Q3 2025 | -$1.17 | +$3.28 |
| Q2 2025 | -$2.38 | +$0.54 |
| Q1 2025 | -$2.76 | -$0.31 |
| Q4 2024 | -$4.02 | -$3.08 |
MPT has returned to profit: it earned $0.41 per share over the past year, after losing money the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the edge over MPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over MPT on profitability, with a higher operating margin.
MPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $250.1M | +5.3% |
| Q2 2026 | $259.3M | +7.9% |
| Q1 2026 | $252.1M | +13% |
| Q4 2025 | $270.3M | +17% |
| Q3 2025 | $237.5M | +5.2% |
| Q2 2025 | $240.4M | -9.8% |
| Q1 2025 | $223.8M | -18% |
| Q3 2024 | $225.8M | -26% |
MPT's revenue is recovering but still below its 2022 peak: $250M last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5.5% | -1.9 points |
| Q2 2026 | 3.3% | +0.5 points |
| Q1 2026 | 2.7% | +5.2 points |
| Q4 2025 | 14% | +1.8 points |
| Q3 2025 | -3.6% | +53 points |
| Q2 2025 | 2.9% | -4.6 points |
| Q1 2025 | -2.5% | -21 points |
| Q4 2024 | 12% | N/A |
MPT's operating margin was −5.5% last quarter, down 1.9 points from the same quarter a year ago, near the bottom of its range since 2019.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
MPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $41.1M | +122% |
| Q2 2026 | $62.4M | +21% |
| Q1 2026 | -$14.3M | -3813% |
| Q4 2025 | $160.1M | +109% |
| Q3 2025 | $18.6M | -69% |
| Q2 2025 | $51.7M | +47% |
| Q1 2025 | $384K | -99% |
| Q4 2024 | $76.7M | -43% |
MPT has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over MPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
MPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -799K shares |
| 1 year | -0.7% | -4M shares |
| 3 years | -0.2% | -1.4M shares |
| 5 years | 0% | -158K shares |
| Available history | +21% | +102M shares |
MPT has 597M diluted shares, down 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2023 | $2M |
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM has the edge over MPT on leverage, with a lower net debt burden relative to earnings.
MPT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 27.0x | High |
| Q2 2026 | 28.8x | High |
| Q1 2026 | 29.0x | High |
| Q4 2025 | 30.7x | High |
| Q3 2025 | 32.3x | High |
| Q2 2025 | 30.0x | High |
| Q1 2025 | 24.9x | High |
| Q4 2024 | 20.3x | High |
MPT's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MPT.
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
MPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 14.7 | Oversold |
| Stochastic | 2.8 | Oversold |
MPT's weekly RSI is 15 (oversold) and its Stochastic is 3 (oversold).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
MPT PE vs Financial Services Sector
| Metric | MPT | Sector median | Relative |
|---|---|---|---|
| PE | 4.2x | 13x | 68% below |
| PE % | 0 | 63 | 63 pts below |
MPT has the edge over JPM on valuation relative to its sector.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over MPT on trend strength, trading above more of its moving averages.
MPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.68 | 36% below |
| 20 week MA | $3.65 | 53% below |
| 50 week MA | $4.51 | 62% below |
| 100 week MA | $4.68 | 63% below |
| 200 week MA | $5.44 | 69% below |
MPT is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over MPT on returns for 2026, with the stronger performance.
MPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.7 | $21.7 | +4.9% |
| 2021 | $21.7 | $22.7 | +4.3% |
| 2022 | $22.7 | $11.2 | -51% |
| 2023 | $11.2 | $4.91 | -56% |
| 2024 | $4.91 | $3.73 | -24% |
| 2025 | $3.73 | $5.08 | +36% |
| 2026 YTD | $5.08 | $1.71 | -66% |
MPT has finished lower in three of the last six years. It's down 66% so far in 2026.